#NephJC Transcript

Healthcare social media transcript of the #NephJC hashtag.
().
See #NephJC Influencers/Analytics.

Sign up for FREE Symplur Account and Get
  • Create Transcripts with Custom Dates
  • Get Custom Influencer Lists
  • 3x Hashtag Search Results
Sign Up Now
ProfileTweet
jesse macs @lasvegaskidney
RT @edgarvlermamd: MT @arvindcanchi @ISNeducation ANCA Vasculitis: Factors increasing risk of relapse #Nephpearls #NephJC #WCN2017 🇲🇽 https…
jesse macs @lasvegaskidney
RT @edgarvlermamd: Potential therapeutic targets in ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/CCru5MgPfu https://t.co/gdPYNXFu6H
Dr. Miguel A. Cota:. @macotav
RT @ISNeducation: @edgarvlermamd @arvindcanchi This might be of interest from @macotav https://t.co/cv6m1TCwmg #nephJC #Nephpearls
Ana Maria Matias @AMCMA6
RT @GlomCon1: Tonigh #NephJC will discuss the study of C5a receptor inhibitor in ANCA-associated vasculitis. We look forward to a…
Ana Maria Matias @AMCMA6
RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw
Ana Maria Matias @AMCMA6
RT @edgarvlermamd: MT @arvindcanchi @ISNeducation ANCA Vasculitis: Factors increasing risk of relapse #Nephpearls #NephJC #WCN2017 🇲🇽 https…
Jyoti Baharani @renalpages
RT @edgarvlermamd: ANCA Vasculitis: Predictors of treatment relapse/ resistance #Nephpearls #NephJC https://t.co/sBKk4ek8uS
Héctor Rodrigo @rodrigohector7
RT @JMGardnerMD: RT @BethBraunhut: Gorgeous example of membranous nephropathy. Looks at those spikes! #pathology #pathArt #nephJC https://t…
manuel macia heras @mmacia25
RT @NephJC: Less than 60 minutes to tonight's #NephJC Not too late to read the article: https://t.co/XQIiqDrL5j Or summary: https://t.co/e…
Ana Maria Matias @AMCMA6
RT @ISNeducation: @edgarvlermamd @arvindcanchi This might be of interest from @macotav https://t.co/cv6m1TCwmg #nephJC #Nephpearls
Ana Maria Matias @AMCMA6
RT @NephRodby: Anything that spares or avoids steroids has Holy Grail potential #NephJC
Ana Maria Matias @AMCMA6
RT @NephRodby: Even though we save a life every time we dialyze, nothing is like bringing someone back from the dead from vasculitis #Neph
Tom Oates @toates_19
Join #NephJC tonight to discuss the CLEAR study in #vasculitis 8pm BST Summary: https://t.co/oeSvlMRvEw https://t.co/eUHfgtLOdT
David Warriner @DrDavidWarriner
RT @toates_19: Join #NephJC tonight to discuss the CLEAR study in #vasculitis 8pm BST Summary: https://t.co/oeSvlMRvEw https://t.co/eUHfgtL…
Tom Oates @toates_19
#NephJC on Avacopan in #vasculitis Tonight 8pm BST Summary: https://t.co/oeSvlMRvEw https://t.co/q77EeydZ5I
John@Vasculitis UK @vascuk
RT @toates_19: Join #NephJC tonight to discuss the CLEAR study in #vasculitis 8pm BST Summary: https://t.co/oeSvlMRvEw https://t.co/eUHfgtL…
Julian W @waldjm
RT @toates_19: Join #NephJC tonight to discuss the CLEAR study in #vasculitis 8pm BST Summary: https://t.co/oeSvlMRvEw https://t.co/eUHfgtL…
Tom Oates @toates_19
#nephjc https://t.co/8yEyIPa6Dh
Trinity Kidneys @THKC1
RT @toates_19: Join #NephJC tonight to discuss the CLEAR study in #vasculitis 8pm BST Summary: https://t.co/oeSvlMRvEw https://t.co/eUHfgtL…
Sanjeev Nair @Nair_Sanj
@KidneyCathy I am sure 1 of them did given I am the father. Not very sure about his mother though. #nephjc in the morning didn't exactly endear me 2 her😂
Fede P.S. @Sensingcrackest
RT @edgarvlermamd: @NephRodby Potential therapeutic targets in ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/CCru5MyqE4 https://t.co/…
Trinity Kidneys @THKC1
RT @edgarvlermamd: Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC 👉🏼…
Matt Graham-Brown @DrMattGB
RT @toates_19: #NephJC on Avacopan in #vasculitis Tonight 8pm BST Summary: https://t.co/oeSvlMRvEw https://t.co/q77EeydZ5I
Basu Gopal @BasuNephro
RT @ISNeducation: @edgarvlermamd @arvindcanchi This might be of interest from @macotav https://t.co/cv6m1TCwmg #nephJC #Nephpearls
Basu Gopal @BasuNephro
RT @edgarvlermamd: Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC 👉🏼…
Basu Gopal @BasuNephro
RT @edgarvlermamd: Flow diagram for treatment of ANCA Vasculitis ca. 2015 #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/qmnoD…
Basu Gopal @BasuNephro
RT @kidney_boy: This study is the tip of the spear. We are interested in it because it's a whole new promising drug. Very exciting. #nephjc
Dr.Ling @wenxinv
RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw
Ernesto LopezAlmaraz @kidney_doctor
RT @edgarvlermamd: Flow diagram for treatment of ANCA Vasculitis ca. 2015 #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/qmnoD…
VOD-MD @vod_md
RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw
ANDY LONGFELLOW @dddc3guk
#DDDC3G #DDDC3GUK and #ahus @aHUSAllianceAct also hopefully for the future trials. @GlomCon1 https://t.co/cg9e037w9s
ANDY LONGFELLOW @dddc3guk
RT @BasuNephro: Avacopan - C5a receptor antagonist in ANCA vasculitis https://t.co/3xZBfti3oc
ANDY LONGFELLOW @dddc3guk
RT @toates_19: Join #NephJC tonight to discuss the CLEAR study in #vasculitis 8pm BST Summary: https://t.co/oeSvlMRvEw https://t.co/eUHfgtL…
UmaraniMK @umaranigubbi
RT @JMGardnerMD: RT @BethBraunhut: Gorgeous example of membranous nephropathy. Looks at those spikes! #pathology #pathArt #nephJC https://t…
Luis Raul López @luisraulmt
RT @edgarvlermamd: Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC 👉🏼…
Dearbhla Kelly @DearbhlaKelly4
Join me to tonight (Wed) at 8pm BST for an exciting #NephJC https://t.co/vl692NSgHa
Anace Pastor @anace710
RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw
Anace Pastor @anace710
RT @GlomCon1: Tonigh #NephJC will discuss the study of C5a receptor inhibitor in ANCA-associated vasculitis. We look forward to a…
Swapnil Hiremath, MD, MPH @hswapnil
RT @DearbhlaKelly4: Join me to tonight (Wed) at 8pm BST for an exciting #NephJC https://t.co/vl692NSgHa
BSR @rheumatologyuk
RT @toates_19: Join #NephJC tonight to discuss the CLEAR study in #vasculitis 8pm BST Summary: https://t.co/oeSvlMRvEw https://t.co/eUHfgtL…
Fra Ian 🇪🇺 @caioqualunque
RT @toates_19: #NephJC on Avacopan in #vasculitis Tonight 8pm BST Summary: https://t.co/oeSvlMRvEw https://t.co/q77EeydZ5I
Liz Lightstone #PeoplesVote @kidneydoc101
RT @toates_19: #NephJC on Avacopan in #vasculitis Tonight 8pm BST Summary: https://t.co/oeSvlMRvEw https://t.co/q77EeydZ5I
Ester Sifuentes @t_tsita
RT @edgarvlermamd: Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC 👉🏼…
Sanjeev Nair @Nair_Sanj
RT @ISNeducation: @edgarvlermamd @arvindcanchi This might be of interest from @macotav https://t.co/cv6m1TCwmg #nephJC #Nephpearls
Ester Sifuentes @t_tsita
RT @NephJC: Can a rheumatologist comment on the suitability of the Birmingham score for acute change? #nephJC #RheumJC
Ester Sifuentes @t_tsita
RT @edgarvlermamd: C-ANCA Chocolate chip cookie 🍪 P-ANCA Popcorn 🍿 Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs
Manan Doshi @manan_doshi
RT @ISNeducation: @edgarvlermamd @arvindcanchi This might be of interest from @macotav https://t.co/cv6m1TCwmg #nephJC #Nephpearls
Sandra Muñoz López @ssanml
RT @edgarvlermamd: Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC 👉🏼…
丹れちモㄥ爪◯ ㄥóㄗモ乙 @DrAnselmoLopez
RT @edgarvlermamd: C-ANCA Chocolate chip cookie 🍪 P-ANCA Popcorn 🍿 Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs
Kevin J. Fowler @gratefull080504
@VasculitisIA @VasculitisUK @vascuk @VasculitisFound @UKvasculiti : Here is the #storify from last night's #nephJC chat #vasculitis https://t.co/GF6RFOiJOA
PCCM @PedCritCareMed
The August @PedCritCareMed is out today, with FREE Feature Articles on their way! https://t.co/tS4CbqgIHl #sepsis #nephJC #airway #PedsICU https://t.co/7fWpmVVw0x
Sapna Kudchadkar, MD, PhD 👩🏽‍⚕️ @SapnaKmd
RT @PedCritCareMed: The August @PedCritCareMed is out today, with FREE Feature Articles on their way! https://t.co/tS4CbqgIHl #sepsis
Alice Ackerman, MD, @closetohomemd
RT @PedCritCareMed: The August @PedCritCareMed is out today, with FREE Feature Articles on their way! https://t.co/tS4CbqgIHl #sepsis
Kevin J. Fowler @gratefull080504
Thanks @ASNKidney for sharing the information about the #AskASN chat on #Kidneyweek17 I'll be there #nephJC #KidneyDisease https://t.co/WQtIjcSR4K
Susan Kaczorowski @bp1458
RT @PedCritCareMed: The August @PedCritCareMed is out today, with FREE Feature Articles on their way! https://t.co/tS4CbqgIHl #sepsis
Johns Hopkins PICU @HopkinsPICU
RT @PedCritCareMed: The August @PedCritCareMed is out today, with FREE Feature Articles on their way! https://t.co/tS4CbqgIHl #sepsis
Hopkins PICU Up! @picu_up
RT @PedCritCareMed: The August @PedCritCareMed is out today, with FREE Feature Articles on their way! https://t.co/tS4CbqgIHl #sepsis
Syed Shahrul Naz @drshahrul80
RT @edgarvlermamd: C-ANCA Chocolate chip cookie 🍪 P-ANCA Popcorn 🍿 Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs
Syed Shahrul Naz @drshahrul80
RT @edgarvlermamd: Flow diagram for treatment of ANCA Vasculitis ca. 2015 #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/qmnoD…
Syed Shahrul Naz @drshahrul80
RT @edgarvlermamd: Renal Vasculitis #Nephpearls #NephJC https://t.co/M8K8c5qPBo
Syed Shahrul Naz @drshahrul80
RT @edgarvlermamd: Potential therapeutic targets in ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/CCru5MgPfu https://t.co/gdPYNXFu6H
manuel macia heras @mmacia25
RT @edgarvlermamd: Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC 👉🏼…
Syed Shahrul Naz @drshahrul80
RT @PedCritCareMed: The August @PedCritCareMed is out today, with FREE Feature Articles on their way! https://t.co/tS4CbqgIHl #sepsis
Ana Maria Matias @AMCMA6
RT @edgarvlermamd: Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC 👉🏼…
Ana Maria Matias @AMCMA6
RT @edgarvlermamd: Flow diagram for treatment of ANCA Vasculitis ca. 2015 #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/qmnoD…
Ana Maria Matias @AMCMA6
RT @toates_19: #NephJC on Avacopan in #vasculitis Tonight 8pm BST Summary: https://t.co/oeSvlMRvEw https://t.co/q77EeydZ5I
Kevin J. Fowler @gratefull080504
#KidneyDisease #RareDisease #esrd #vasculitis https://t.co/6Heu7NVHbP
Joel Topf, MD FACP @kidney_boy
Beta #VisualAbstract for tonight's (and last night's) #NephJC Avacopan for ANCA Associated Vasculitis, a phase 2 trial https://t.co/cgfVSqqp4I
Arvind Canchi 🇮🇳 @arvindcanchi
RT @kidney_boy: Beta #VisualAbstract for tonight's (and last night's) #NephJC Avacopan for ANCA Associated Vasculitis, a phase 2 tr…
NBLU: Renal Leaders @NBLUniv
Great example of a #visualabstract!What font is that on the top line? https://t.co/ikxb83GMsH
Raj Mehta, MD @raj_mehta
RT @kidney_boy: Beta #VisualAbstract for tonight's (and last night's) #NephJC Avacopan for ANCA Associated Vasculitis, a phase 2 tr…
Sibel Gokcay Bek @sibgokcay
RT @kidney_boy: Beta #VisualAbstract for tonight's (and last night's) #NephJC Avacopan for ANCA Associated Vasculitis, a phase 2 tr…
Fadel Alrowaie @fadelrowaie
RT @edgarvlermamd: C-ANCA Chocolate chip cookie 🍪 P-ANCA Popcorn 🍿 Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs
Haneen Al.Maghrabi @Haneen_Maghrabi
RT @edgarvlermamd: C-ANCA Chocolate chip cookie 🍪 P-ANCA Popcorn 🍿 Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs
Fadel Alrowaie @fadelrowaie
RT @edgarvlermamd: Flow diagram for treatment of ANCA Vasculitis ca. 2015 #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/qmnoD…
Fadel Alrowaie @fadelrowaie
RT @edgarvlermamd: Renal Vasculitis #Nephpearls #NephJC https://t.co/M8K8c5qPBo
Jose Ignacio @joigperal
RT @JMGardnerMD: RT @BethBraunhut: Gorgeous example of membranous nephropathy. Looks at those spikes! #pathology #pathArt #nephJC https://t…
amer mansour @am_altamimi
RT @edgarvlermamd: Flow diagram for treatment of ANCA Vasculitis ca. 2015 #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/qmnoD…
Andrew M. Ibrahim MD @AndrewMIbrahim
RT @kidney_boy: Beta #VisualAbstract for tonight's (and last night's) #NephJC Avacopan for ANCA Associated Vasculitis, a phase 2 tr…
UVA PICU @uva_picu
RT @PedCritCareMed: The August @PedCritCareMed is out today, with FREE Feature Articles on their way! https://t.co/tS4CbqgIHl #sepsis
Mana @manasigh
RT @edgarvlermamd: Potential therapeutic targets in ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/CCru5MgPfu https://t.co/gdPYNXFu6H
Brian Walsh RRT PhD @briankwalsh
RT @PedCritCareMed: The August @PedCritCareMed is out today, with FREE Feature Articles on their way! https://t.co/tS4CbqgIHl #sepsis
Ana of House Stark 🐺 @CrissSoto
RT @PedCritCareMed: The August @PedCritCareMed is out today, with FREE Feature Articles on their way! https://t.co/tS4CbqgIHl #sepsis
Mark Derks @superpleeg
RT @PedCritCareMed: The August @PedCritCareMed is out today, with FREE Feature Articles on their way! https://t.co/tS4CbqgIHl #sepsis
Rob Peel🏳️‍🌈 @rabpeel
On holiday , a shame because @NHSHRenal is part of a trial with it https://t.co/95eWwAjSO1
Tom Oates @toates_19
RT @kidney_boy: Beta #VisualAbstract for tonight's (and last night's) #NephJC Avacopan for ANCA Associated Vasculitis, a phase 2 tr…
Mo Alzubaidi @NephrosisMo
RT @kidney_boy: Beta #VisualAbstract for tonight's (and last night's) #NephJC Avacopan for ANCA Associated Vasculitis, a phase 2 tr…
Kevin J. Fowler @gratefull080504
@KidneyPatients @RSNhope @PKDFoundation @KidneyResInst @kidneystories @GKH_org Hope you can join the conversation! #askasn #NephJC https://t.co/vp0A3rfXUa
Nephrology Jrnl Club @NephJC
T-90 minutes to #NephJC on Avacopan as a steroid alternative in ANCA vasculitis! All welcome!
Richard McCrory @iamdoctord
RT @kidney_boy: Beta #VisualAbstract for tonight's (and last night's) #NephJC Avacopan for ANCA Associated Vasculitis, a phase 2 tr…
Ana Maria Matias @AMCMA6
RT @manirath: @NephJC Ritux has come in big way. Now the first line of tx #NephJC
Richard McCrory @iamdoctord
Kudos to @toates_19 directing #nephjc fraternity to @f2harrell's statistics blog for some highly informative reading pre-Avacopan discussion
Richard McCrory @iamdoctord
RT @gratefull080504: Thanks @ASNKidney for sharing the information about the #AskASN chat on #Kidneyweek17 I'll be there #nephJC
Swapnil Hiremath, MD, MPH @hswapnil
RT @iamdoctord: Kudos to @toates_19 directing #nephjc fraternity to @f2harrell's statistics blog for some highly informative reading pre-Av…
Dearbhla Kelly @DearbhlaKelly4
RT @kidney_boy: Beta #VisualAbstract for tonight's (and last night's) #NephJC Avacopan for ANCA Associated Vasculitis, a phase 2 tr…
Jim Myers @kidneystories
RT @gratefull080504: @KidneyPatients @RSNhope @PKDFoundation @KidneyResInst @kidneystories @GKH_org Hope you can join the conversation!…
Richard McCrory @iamdoctord
RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw
Nephrology Jrnl Club @NephJC
Welcome to #NephJC tonight! I @DearbhlaKelly4 will be your host. Please introduce yourself and declare any COI.
Nephrology Jrnl Club @NephJC
Tonight we are discussing Avacopan in ANCA-associated vasculitis. You can read the paper at https://t.co/XQIiqDrL5j #NephJC
Matt Graham-Brown @DrMattGB
RT @NephJC: Welcome to #NephJC tonight! I @DearbhlaKelly4 will be your host. Please introduce yourself and declare any COI.
Nephrology Jrnl Club @NephJC
Or read or @toates_19 wonderful summary here https://t.co/ebwCRF1adF #NephJC
Fra Ian 🇪🇺 @caioqualunque
Francesco Iannuzzella, Nephrologist from Italy. No COI #nephjc
Richard McCrory @iamdoctord
Richard, nephron in Belfast, mostly lurking methinks #nephjc
Matt Graham-Brown @DrMattGB
Evening, Matt GB, still on a teleconference, but will be there in full shortly. No COI #NephJC
Matt Graham-Brown @DrMattGB
RT @NephJC: Or read or @toates_19 wonderful summary here https://t.co/ebwCRF1adF #NephJC
John@Vasculitis UK @vascuk
@NephJC @DearbhlaKelly4 #NephJC John Mills Chairman of Vasculitis UK and Vasculitis Patient
Alexander Kirsch @alehkir
Alex Kirsch, Graz, Austria; on call so mostly lurking, no COI #nephjc
OmarTaco MD, MSc @Errantnephron
@NephJC @DearbhlaKelly4 Hi! Omar Taco, nephrologist in Barcelona, today only lurking #NephJC https://t.co/ZV7mpIx7qa
Nephrology Jrnl Club @NephJC
We recommend using https://t.co/rFoH4MVMzu or TChat.io to follow the #nephjc chat. See a how to guide here: http//www.nephjc.com/how-to/
Matt Graham-Brown @DrMattGB
@DearbhlaKelly4 - the hardest working Renal SpR in the UK. Multi-tasking a TC and hosting! #tekkers #nephJC https://t.co/TojLYEkLC4
Swapnil Hiremath, MD, MPH @hswapnil
Swapnil Hiremath from @OttawaHospital Lurking, but trying to make up for missing last night #NephJC https://t.co/cYKKd6X2Ru
Tomas Rohal @calvapo
@NephJC @DearbhlaKelly4 Happy to see you all, Tomas in Prague, probably just lurking b/o other duties #nephjc
Swapnil Hiremath, MD, MPH @hswapnil
RT @NephJC: Or read or @toates_19 wonderful summary here https://t.co/ebwCRF1adF #NephJC
Nephrology Jrnl Club @NephJC
Let's kick off! T0: Steroids are the driving force for morbidity/mortality now in AAV. Who agrees? #NephJC
soda_troubles @set_fortess
RT @NephJC: Or read or @toates_19 wonderful summary here https://t.co/ebwCRF1adF #NephJC
Swapnil Hiremath, MD, MPH @hswapnil
@vascuk thanks for joining - and contributing to the @NephJC commentary! https://t.co/qyGAq881C8 @DearbhlaKelly4 #nephjc
Nephrology Jrnl Club @NephJC
RT @hswapnil: @vascuk thanks for joining - and contributing to the @NephJC commentary! https://t.co/qyGAq881C8 @DearbhlaKelly4 #nephjc
Swapnil Hiremath, MD, MPH @hswapnil
T0: not sure. AAV pretty bad and nasty by itself (esp the renal cases seen by us). Steroids bad, AAV badder? #nephjc
Matt Graham-Brown @DrMattGB
T0: I agree. Morbidity associated with steroids high. Infections, bones, diabetes etc. All bad stuff #NephJC
Nephrology Jrnl Club @NephJC
T0: the greatest threat to patients with AAV in their first year is adverse tx events #nephjc https://t.co/45gqAenklM
Swapnil Hiremath, MD, MPH @hswapnil
RT @DrMattGB: T0: I agree. Morbidity associated with steroids high. Infections, bones, diabetes etc. All bad stuff #NephJC
John@Vasculitis UK @vascuk
#NephJC T0 steroids can be a life saver at the beginning but can be killers in the long run
Nephrology Jrnl Club @NephJC
RT @hswapnil: T0: not sure. AAV pretty bad and nasty by itself (esp the renal cases seen by us). Steroids bad, AAV badder? #nephjc
Swapnil Hiremath, MD, MPH @hswapnil
RT @vascuk: #NephJC T0 steroids can be a life saver at the beginning but can be killers in the long run
Richard McCrory @iamdoctord
RT @NephJC: Let's kick off! T0: Steroids are the driving force for morbidity/mortality now in AAV. Who agrees? #NephJC
Tomas Rohal @calvapo
@hswapnil I agree, esp. in the elderly and short-term complications #nephjc
Richard McCrory @iamdoctord
RT @vascuk: #NephJC T0 steroids can be a life saver at the beginning but can be killers in the long run
Nephrology Jrnl Club @NephJC
T0: From EUVAS trials, 41% had hypertension, 38% osteoporosis, 28% diabetes mellitus and 25% had cataracts. #NephJC https://t.co/wNL6QYcxEJ
Nephrology Jrnl Club @NephJC
RT @DrMattGB: T0: I agree. Morbidity associated with steroids high. Infections, bones, diabetes etc. All bad stuff #NephJC
Matt Graham-Brown @DrMattGB
RT @vascuk: #NephJC T0 steroids can be a life saver at the beginning but can be killers in the long run
Nephrology Jrnl Club @NephJC
RT @vascuk: #NephJC T0 steroids can be a life saver at the beginning but can be killers in the long run
Alexander Kirsch @alehkir
mostly agree; especially in long-term with frequent relapses. terrible infectious complications, bones; #nephjc
John@Vasculitis UK @vascuk
RT @NephJC: T0: From EUVAS trials, 41% had hypertension, 38% osteoporosis, 28% diabetes mellitus and 25% had cataracts. #NephJC https://t.c…
Fra Ian 🇪🇺 @caioqualunque
T0: agree, but we use such powerful and dangerous induction therapy for a reason. Vasculitis may kill #nephjc
Nephrology Jrnl Club @NephJC
T0: Avacopan -small-molecule C5aR antagonist that blocks the effects of C5a, reducing neutrophil activation, accumulation & adhesion #NephJC
Nathaniel Reisinger, MD, FASN @nephrothaniel
Nathaniel Reisinger. Nephrologist and clinical ultrasound fellow @PennKidney no pertinent COI #NephJC
Tomas Rohal @calvapo
RT @NephJC: T0: Avacopan -small-molecule C5aR antagonist that blocks the effects of C5a, reducing neutrophil activation, accumulation & adh…
John@Vasculitis UK @vascuk
RT @caioqualunque: T0: agree, but we use such powerful and dangerous induction therapy for a reason. Vasculitis may kill #nephjc
Richard McCrory @iamdoctord
Wider aspects too. Psychological difficulties often under-reported. #nephjc https://t.co/Ny9VT3jTY2
Swapnil Hiremath, MD, MPH @hswapnil
RT @caioqualunque: T0: agree, but we use such powerful and dangerous induction therapy for a reason. Vasculitis may kill #nephjc
Nephrology Jrnl Club @NephJC
T0: Complement - the hipster bruncher of the immunology world at the moment! #NephJC
Swapnil Hiremath, MD, MPH @hswapnil
RT @NephJC: T0: Avacopan -small-molecule C5aR antagonist that blocks the effects of C5a, reducing neutrophil activation, accumulation & adh…
John@Vasculitis UK @vascuk
#NephJC T0 Biologics reduce the need for long term/high dose steroids
Nephrology Jrnl Club @NephJC
T1: Moving on to methods - Randomised, phase II, double-blind, placebo-controlled, trial running from 2011-2016 #NephJC
Richard McCrory @iamdoctord
Clinical judgement here critical. Risks of disease vs risks of treatment #nephjc
Richard McCrory @iamdoctord
RT @NephJC: T0: From EUVAS trials, 41% had hypertension, 38% osteoporosis, 28% diabetes mellitus and 25% had cataracts. #NephJC https://t.c…
Louise Oni @louise_oni
RT @edgarvlermamd: C-ANCA Chocolate chip cookie 🍪 P-ANCA Popcorn 🍿 Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs
Nephrology Jrnl Club @NephJC
T1: Interesting study design as exemplified in @kidney_boy visual abstract. Tx for just 12 wks #NephJC https://t.co/rLdiakG1gr
Swapnil Hiremath, MD, MPH @hswapnil
RT @NephJC: T1: Interesting study design as exemplified in @kidney_boy visual abstract. Tx for just 12 wks #NephJC https://t.co/rLdiakG1gr
Nephrology Jrnl Club @NephJC
RT @vascuk: #NephJC T0 Biologics reduce the need for long term/high dose steroids
Fra Ian 🇪🇺 @caioqualunque
T0: This sentence is certainly true, but terribly misleading #nephjc https://t.co/xw9dfGPDMA
Nephrology Jrnl Club @NephJC
@vascuk True but they seem to not be enough to prevent relapse? #NephJC
Matt Graham-Brown @DrMattGB
RT @iamdoctord: Wider aspects too. Psychological difficulties often under-reported. #nephjc https://t.co/Ny9VT3jTY2
Nephrology Jrnl Club @NephJC
RT @iamdoctord: Clinical judgement here critical. Risks of disease vs risks of treatment #nephjc
Louise Oni @louise_oni
#NephJC Louise Oni Paeds Neph from Alder Hey children's hospital U.K. ... following with lots of interest 😃
Matt Graham-Brown @DrMattGB
RT @iamdoctord: Clinical judgement here critical. Risks of disease vs risks of treatment #nephjc
Joel Topf, MD FACP @kidney_boy
@caioqualunque Help me out why is that both misleading and true? It was striking. I came this close to tweeting yesterday. #nephjc
John@Vasculitis UK @vascuk
RT @NephJC: T1: Interesting study design as exemplified in @kidney_boy visual abstract. Tx for just 12 wks #NephJC https://t.co/rLdiakG1gr
Matt Graham-Brown @DrMattGB
@NephJC Lol #nephjc
Swapnil Hiremath, MD, MPH @hswapnil
@louise_oni Hey Louise, thanks for joining in! Welcome to #NephJC
Richard McCrory @iamdoctord
T1 It's a complex study arrangement for a small patient cohort #nephjc
Nephrology Jrnl Club @NephJC
T1: What isn't clear from me from the methods is whether patients got methylprednisolone during induction with cyclophosphamide? #NephJC
Richard McCrory @iamdoctord
RT @caioqualunque: T0: This sentence is certainly true, but terribly misleading #nephjc https://t.co/xw9dfGPDMA
Nephrology Jrnl Club @NephJC
T1: Primary endpoint chosen was a decrease in Birmingham Vasculitis Activity Score of 50% or more – any issues with this? #NephJC
Joel Topf, MD FACP @kidney_boy
Searched the whole document and the word methylprednisone wasn't used. #nephjc
Nephrology Jrnl Club @NephJC
RT @caioqualunque: T0: This sentence is certainly true, but terribly misleading #nephjc https://t.co/xw9dfGPDMA
Richard McCrory @iamdoctord
RT @NephJC: Methodology set up for one outcome - but results extrapolated to another. Thx @poyanmehr #nephjc https://t.co/oeSxkJWyJp
Swapnil Hiremath, MD, MPH @hswapnil
@kidney_boy @caioqualunque I am w/ Francesco. Citation 2: https://t.co/p8A7ImQ4qu true: infection > vascultitis misleading: would have likely died without Rx #NephJC https://t.co/hMTbiQnDED
Arinarami @nephrologyunit
RT @NephJC: T-90 minutes to #NephJC on Avacopan as a steroid alternative in ANCA vasculitis! All welcome!
Nephrology Jrnl Club @NephJC
RT @iamdoctord: T1 It's a complex study arrangement for a small patient cohort #nephjc
Swapnil Hiremath, MD, MPH @hswapnil
RT @NephJC: Methodology set up for one outcome - but results extrapolated to another. Thx @poyanmehr #nephjc https://t.co/oeSxkJWyJp
John@Vasculitis UK @vascuk
T1 #NephJC BVA is a good reliable indicator for research purposes although not so good as a diagnostic tool
Matt Graham-Brown @DrMattGB
BVAS is good. distils lots of disparate symptoms to a number. Of course this loses detail & sensitivity, but good tool and validated #nephjc https://t.co/EPyFVlYQcG
Fra Ian 🇪🇺 @caioqualunque
@kidney_boy The reader must recognize/know what, for me, you & other nephrons is a logical premise: mortality would be higher w/out treatment. #nephjc
Alexander Kirsch @alehkir
@NephJC True, isn't clear at all. But I can't imagine that they would get approval at that point in time to do steroid free induction. #nephJC
Swapnil Hiremath, MD, MPH @hswapnil
RT @vascuk: T1 #NephJC BVA is a good reliable indicator for research purposes although not so good as a diagnostic tool
Nephrology Jrnl Club @NephJC
A single dose of MP can have lasting effects on immunity. It would be important to define if there was truly a steroid free arm #NephJC https://t.co/q6vh8Xka7g
Alexander Kirsch @alehkir
@caioqualunque #nephJC misleading b/c in spite of treatment-associated morbidity/mortality hard to argue: what would have happened w/o current treatments?
Nephrology Jrnl Club @NephJC
RT @hswapnil: @kidney_boy @caioqualunque I am w/ Francesco. Citation 2: https://t.co/p8A7ImQ4qu true: infection > vascultitis mi…
Nephrology Jrnl Club @NephJC
RT @poyanmehr: @NephJC @kidney_boy that is where the confusion comes in. clearly not powered & designed for what we would like to see #nep
Swapnil Hiremath, MD, MPH @hswapnil
RT @alehkir: @caioqualunque #nephJC misleading b/c in spite of treatment-associated morbidity/mortality hard to argue: what woul…
Richard McCrory @iamdoctord
@NephJC T1: Not up to speed with how quickly or not BVAS changes during Tx, or if a point BVAS measure reliably reflects day-to-day pt state #nephjc
Richard McCrory @iamdoctord
RT @alehkir: @caioqualunque #nephJC misleading b/c in spite of treatment-associated morbidity/mortality hard to argue: what woul…
Nephrology Jrnl Club @NephJC
RT @DrMattGB: BVAS is good. distils lots of disparate symptoms to a number. Of course this loses detail & sensitivity, but good t…
Matt Graham-Brown @DrMattGB
RT @vascuk: T1 #NephJC BVA is a good reliable indicator for research purposes although not so good as a diagnostic tool
Nephrology Jrnl Club @NephJC
RT @iamdoctord: @NephJC T1: Not up to speed with how quickly or not BVAS changes during Tx, or if a point BVAS measure reliably ref…
Nephrology Jrnl Club @NephJC
T1: If the study had used a pre-specified BVAS scores of 0 instead of relative change, would this have been more compelling? #NephJC
Richard McCrory @iamdoctord
@NephJC What would the ethical implications of that be? #nephjc
Fra Ian 🇪🇺 @caioqualunque
T1: I didn't like BVAS, but EUVAS made such a great work to demonstrate its validity, we can't reject it #nephjc
Matt Graham-Brown @DrMattGB
@iamdoctord @NephJC Not an expert but am led to believe it's a good marker of disease activity and multi-system #NephJC
Nephrology Jrnl Club @NephJC
T1: Analysis was intention to treat and based on non-inferiority #NephJC
Matt Graham-Brown @DrMattGB
Yep. Phase 2. #nephjc https://t.co/SdexkSrBru
Swapnil Hiremath, MD, MPH @hswapnil
@NephJC BVAS quite well accepted/validated (though I am w/ @DrMattGB on not being an expert on this; research tool > clinical use) #NephJC https://t.co/kcoBYO5eEk
Richard McCrory @iamdoctord
RT @hswapnil: @NephJC BVAS quite well accepted/validated (though I am w/ @DrMattGB on not being an expert on this; research tool…
Matt Graham-Brown @DrMattGB
RT @hswapnil: @NephJC BVAS quite well accepted/validated (though I am w/ @DrMattGB on not being an expert on this; research tool…
Nephrology Jrnl Club @NephJC
RT @caioqualunque: T1: I didn't like BVAS, but EUVAS made such a great work to demonstrate its validity, we can't reject it #nephjc
Nephrology Jrnl Club @NephJC
RT @hswapnil: @NephJC BVAS quite well accepted/validated (though I am w/ @DrMattGB on not being an expert on this; research tool…
Alexander Kirsch @alehkir
@NephJC #nephJC @toates_19 pointed out what the problem with the chosen endpoint is in the nephJC summary.
Matt Graham-Brown @DrMattGB
@NephJC Ok, fair shout. will hope @kidneydoc101 offers an opinion maybe at a later date! #NephJC
Richard McCrory @iamdoctord
@hswapnil @NephJC @DrMattGB Agree w/ @psufka "any tool that tries to convert how a pt is doing to a number will always be flawed." #nephjc
Tomas Rohal @calvapo
@hswapnil @NephJC @DrMattGB not that used to it in practice here - possibly big room for uncertainty in some s/s in your practice? #nephJC
Swapnil Hiremath, MD, MPH @hswapnil
@NephJC Ah, 20% non-inferiority (same as RAVE ). Time for me to roll out the non-inferiority must read https://t.co/uEBHVQoHIB #nephjc https://t.co/8Ppq2l7e1S
Matt Graham-Brown @DrMattGB
@iamdoctord @hswapnil @NephJC @psufka I think flawed is a bit strong. Lose detail sure, but for trials you need to distil complexity to make it understandable 1/2 #nephjc
Nephrology Jrnl Club @NephJC
T2: Here is @toates_19 summary of efficacy findings. 'Tx response' seen in high proportion in all 3 grips #nephjc https://t.co/KaaTqs8Eqm
Swapnil Hiremath, MD, MPH @hswapnil
#NephJC https://t.co/KcvQTJ6AO2
Richard McCrory @iamdoctord
RT @hswapnil: @NephJC Ah, 20% non-inferiority (same as RAVE ). Time for me to roll out the non-inferiority must read…
Nephrology Jrnl Club @NephJC
RT @iamdoctord: @hswapnil @NephJC @DrMattGB Agree w/ @psufka "any tool that tries to convert how a pt is doing to a number will always be f…
Swapnil Hiremath, MD, MPH @hswapnil
RT @iamdoctord: @hswapnil @NephJC @DrMattGB Agree w/ @psufka "any tool that tries to convert how a pt is doing to a number will always be f…
Nephrology Jrnl Club @NephJC
RT @hswapnil: @NephJC Ah, 20% non-inferiority (same as RAVE ). Time for me to roll out the non-inferiority must read…
Fra Ian 🇪🇺 @caioqualunque
@iamdoctord @f2harrell T1: I wonder whether this study could be made w/ a Bayesian design, given the pts number. I've to admit I've no idea on how to do it #nephjc
Matt Graham-Brown @DrMattGB
@iamdoctord @hswapnil @NephJC @psufka BVAS does a good (imperfect) job of measuring a tonne of things and turning it into an interpretable/analysable score. #nephjc 2/2
Nephrology Jrnl Club @NephJC
T2: Mostly new diagnoses though some relapses with equal split MPO and PR3 #NephJC
John@Vasculitis UK @vascuk
RT @DrMattGB: @iamdoctord @hswapnil @NephJC @psufka BVAS does a good (imperfect) job of measuring a tonne of things and turning i…
Swapnil Hiremath, MD, MPH @hswapnil
RT @NephJC: T2: Here is @toates_19 summary of efficacy findings. 'Tx response' seen in high proportion in all 3 grips #nephjc https://t.co/…
Matt Graham-Brown @DrMattGB
@caioqualunque @iamdoctord @f2harrell Lol, you're not alone there! #NephJC
Fra Ian 🇪🇺 @caioqualunque
@kidney_boy I only found the word "kidney" in the references list 🤔#nephjc
Vasculitis Stichting @vasculitis_nl
RT @caioqualunque: T0: This sentence is certainly true, but terribly misleading #nephjc https://t.co/xw9dfGPDMA
John@Vasculitis UK @vascuk
@caioqualunque @iamdoctord @f2harrell #NephJC numbers were very small but phase 3 will provide strength of numbers for convincing evidence
Matt Graham-Brown @DrMattGB
RT @hswapnil: @NephJC Ah, 20% non-inferiority (same as RAVE ). Time for me to roll out the non-inferiority must read…
Nephrology Jrnl Club @NephJC
T2: only key diff between groups was that placebo + pred group had worse renal disease at baseline but Ava renally protective? #NephJC
Ross Morton @signindoc
RT @iamdoctord: @hswapnil @NephJC @DrMattGB Agree w/ @psufka "any tool that tries to convert how a pt is doing to a number will always be f…
Alexander Kirsch @alehkir
@NephJC yes; quite surprising to find MPO and PR3 so well balanced; #nephJC
Fra Ian 🇪🇺 @caioqualunque
@vascuk @iamdoctord @f2harrell This was a sponsored trial. Is this the first to be sponsored in vasculitis? #nephjc
Nephrology Jrnl Club @NephJC
Yes it's reassuring for PR3 patients albeit too short a trial to compare relapse rates #NephJC https://t.co/kz8j9CdNxE
Nephrology Jrnl Club @NephJC
T2: Seems to be safe. Adverse events were similar across all groups, with 17% (4/23) control patients and 25% (11/44) ava patients #NephJC
John@Vasculitis UK @vascuk
@caioqualunque @iamdoctord @f2harrell #NephJC was RTX not sponsored - if only indirectly?
Nephrology Jrnl Club @NephJC
T2: Fewer side effects related to GC use were seen in patients on Ava (34% v 65%). Mainly fewer psych disorders and new DM. #NephJC
Gates Colbert, MD @DoctorGates
Dallas based Nephrologist. Lurking today and participating last night. #NephJC
Nephrology Jrnl Club @NephJC
RT @caioqualunque: T0: agree, but we use such powerful and dangerous induction therapy for a reason. Vasculitis may kill #nephjc
Fra Ian 🇪🇺 @caioqualunque
T2: inclusion criteria: pts with kidney biopsy OR signs of renal disease, how many biopsies were made? I was unable to find it #NephJC
Tomas Rohal @calvapo
@NephJC This sounds very good to me - some of those important aspects as far as QoL is concerned #nephJC
Alexander Kirsch @alehkir
@vascuk @caioqualunque @iamdoctord @f2harrell Roche was funding for Jones EUVAS study #nephJC
Nephrology Jrnl Club @NephJC
Yes RITUXVAS was sponsored by La Roche I believe #NephJC https://t.co/4ilWn4B4gb
Richard McCrory @iamdoctord
@caioqualunque didn't see a figure.. #nephjc
Nephrology Jrnl Club @NephJC
RT @caioqualunque: T2: inclusion criteria: pts with kidney biopsy OR signs of renal disease, how many biopsies were made? I was unable to f…
Nephrology Jrnl Club @NephJC
RT @alehkir: @vascuk @caioqualunque @iamdoctord @f2harrell Roche was funding for Jones EUVAS study #nephJC
Fra Ian 🇪🇺 @caioqualunque
T2: did patients treated w/ avacopan need vaccination like with eculizumab? #nephjc
Nephrology Jrnl Club @NephJC
T2: Interestingly, more lymphopenia with avacopan compared with control/steroid group. Any explanations for this? #NephJC
Matt Graham-Brown @DrMattGB
@caioqualunque That is a good question to which I do not know the answer! #NephJC
Nephrology Jrnl Club @NephJC
Really good point Fra! I didn't see that in study protocol? #nephJC https://t.co/BaDylLkCyH
Alexander Kirsch @alehkir
@caioqualunque we're participating in the f/u study: no evidence of increased susc to bact meningitis w avacopan; don't need vaccinations #nephjc
Fra Ian 🇪🇺 @caioqualunque
RT @alehkir: @caioqualunque we're participating in the f/u study: no evidence of increased susc to bact meningitis w avacopan; d…
Matt Graham-Brown @DrMattGB
@alehkir @caioqualunque Thanks #nephjc
Nephrology Jrnl Club @NephJC
@Edwinwong00 will definitely know the answer to this! #NephJC
Nephrology Jrnl Club @NephJC
RT @alehkir: @caioqualunque we're participating in the f/u study: no evidence of increased susc to bact meningitis w avacopan; d…
Alexander Kirsch @alehkir
@caioqualunque guess, probably because only chemotactic complement action is blocked; not formation of C5b-9; #nephJC
Fra Ian 🇪🇺 @caioqualunque
RT @alehkir: @caioqualunque guess, probably because only chemotactic complement action is blocked; not formation of C5b-9; #nephJC
Nephrology Jrnl Club @NephJC
T3: So is this a win for Avacopan to replace high dose steroids? Chemocentryx certainly seem to think so with phase 3 studies #NephJC
Tomas Rohal @calvapo
@NephJC any clue about the cost? #nephJC
Nephrology Jrnl Club @NephJC
T3: Definitely some valid statistical concerns as outlined by @toates_19 on their choice of primary outcome for a short study period #NephJC
Nephrology Jrnl Club @NephJC
Don't think we know yet #NephJC https://t.co/ELYbgWxEtH
Matt Graham-Brown @DrMattGB
'Win' - like it! It's a successful phase 2 study and phase 3 on the way. We musy all wait patiently (or impatiently) before deciding #nephjc https://t.co/CSTJK39Cio
Swapnil Hiremath, MD, MPH @hswapnil
RT @alehkir: @caioqualunque guess, probably because only chemotactic complement action is blocked; not formation of C5b-9; #nephJC
OmarTaco MD, MSc @Errantnephron
@calvapo @NephJC Not yet https://t.co/yXnJv6WmsK #NephJC https://t.co/dqHknBKZnl
Matt Graham-Brown @DrMattGB
@NephJC We could probably make an educated guess! #NephJC
Matt Graham-Brown @DrMattGB
RT @Errantnephron: @calvapo @NephJC Not yet https://t.co/yXnJv6WmsK #NephJC https://t.co/dqHknBKZnl
Nephrology Jrnl Club @NephJC
T3:It will be interesting to see longterm data given that previous concerns about steroid withdrawal were based on withdrawal < 1yr #NephJC
John@Vasculitis UK @vascuk
@NephJC #NephJC NICE are already scoping Avacopan for AAV even though recruiting for phase 3 will not be completed for 2 years
Richard McCrory @iamdoctord
Beaten to the question! #nephjc https://t.co/09LzM8ewYt
Nephrology Jrnl Club @NephJC
https://t.co/qhM7JSPLev #NephJC
Nephrology Jrnl Club @NephJC
RT @DrMattGB: 'Win' - like it! It's a successful phase 2 study and phase 3 on the way. We musy all wait patiently (or impatiently…
Nephrology Jrnl Club @NephJC
RT @Errantnephron: @calvapo @NephJC Not yet https://t.co/yXnJv6WmsK #NephJC https://t.co/dqHknBKZnl
Alexander Kirsch @alehkir
@DrMattGB 12 weeks short period to catch any rare yet maybe serious adverse events; pts need to take this for a long period; still promising #nephJC
Swapnil Hiremath, MD, MPH @hswapnil
T3: not a perfect study. But rare/orphan dz, kudos to sponsor + researchers. Just happy new molecules being tested! #NephForward #nephjc
Alexander Kirsch @alehkir
@DrMattGB agree #nephJC
Matt Graham-Brown @DrMattGB
@vascuk @NephJC For induction? #nephjc
Fra Ian 🇪🇺 @caioqualunque
We all want avacopan win its race over steroids. #nephjc
Nephrology Jrnl Club @NephJC
RT @vascuk: @NephJC #NephJC NICE are already scoping Avacopan for AAV even though recruiting for phase 3 will not be completed for 2 years
Matt Graham-Brown @DrMattGB
@alehkir Yep, all good points #nephjc
Swapnil Hiremath, MD, MPH @hswapnil
Yes! QFT MT @caioqualunque: We all want avacopan to win its race over steroids. #nephjc
Alexander Kirsch @alehkir
@DrMattGB @vascuk @NephJC #nephJC tempting; potential concern that there are no 'culprit' cells being deleted. strong/fast enough?
Fra Ian 🇪🇺 @caioqualunque
On a lateral note: Is steroid tapering schedule in control group comparable to older RCTs? #nephjc. Is there a trend to lower doses?
Nephrology Jrnl Club @NephJC
RT @alehkir: @DrMattGB @vascuk @NephJC #nephJC tempting; potential concern that there are no 'culprit' cells being deleted. strong/fast eno…
Matt Graham-Brown @DrMattGB
@alehkir @vascuk @NephJC These are the next studies I guess. Glad to see the trials coming 👌#NephJC
Matt Graham-Brown @DrMattGB
RT @alehkir: @caioqualunque guess, probably because only chemotactic complement action is blocked; not formation of C5b-9; #nephJC
Nephrology Jrnl Club @NephJC
Time to wrap up I think! Thanks everyone for a really interesting discussion! #NephJC
Tomas Rohal @calvapo
#NephJC https://t.co/WVKoKG4p82
Fra Ian 🇪🇺 @caioqualunque
Theoretically, avacopan could work even in many other immune diseases: are there trials on going? #nephJC
OmarTaco MD, MSc @Errantnephron
@caioqualunque "Standard-dose steroids" is repeated in the paper #NephJC
John@Vasculitis UK @vascuk
@caioqualunque #NephJC if not they should be
Matt Graham-Brown @DrMattGB
@NephJC Thanks @DearbhlaKelly4 - well hosted and excellent summary @toates_19 . Good chat, think we are all quorate on study findings! #nephjc
Tomas Rohal @calvapo
@NephJC Glad to have seen you, thank you and good night to all! #NephJC
John@Vasculitis UK @vascuk
#nephJC will have to leave now as we are involved in another twitter chat shortly, thank you for inviting us, it has been most stimulating
Fra Ian 🇪🇺 @caioqualunque
@DearbhlaKelly4, great chat. Thanks to all. #nephjc
Matt Graham-Brown @DrMattGB
Great to hear views of @alehkir - good insight, thanks 👍👌🖐 #nephjc
Matt Graham-Brown @DrMattGB
Also thanks to @vascuk - great toniave you with us 👏🏻👍👌 #NephJC
Matt Graham-Brown @DrMattGB
@calvapo @NephJC Cheers Tomas, catch you again next time 👍 #nephjc
Fra Ian 🇪🇺 @caioqualunque
@Errantnephron this is from CYCAZAREM now I'll look supplementary files to make a comparison #nephjc. Next tweet in a few minutes https://t.co/xWWTAVbpjI
John@Vasculitis UK @vascuk
@DrMattGB It was a pleasure to take part #NephJC 😊
OmarTaco MD, MSc @Errantnephron
@vascuk @caioqualunque There is one on #NIgA and in #aHUS https://t.co/uUI0GtUGXr #NephJC https://t.co/Lc2yXqKSmS
TOUNSI @tunisiamountain
Tunisian Journal of Medicine est sorti de presse! https://t.co/nGssMCYvCX Les unes d'aujourd'hui via @EMJRheum #arthritis #nephjc
Fra Ian 🇪🇺 @caioqualunque
@Errantnephron Steroid schedule in CLEAR study looks "standard" #nephjc https://t.co/b9JGEExODs
Swapnil Hiremath, MD, MPH @hswapnil
RT @caioqualunque: @Errantnephron Steroid schedule in CLEAR study looks "standard" #nephjc https://t.co/b9JGEExODs
Fra Ian 🇪🇺 @caioqualunque
@Errantnephron But a little bit lower, since PDN doses during the first week in previous RCTs was high as 80 mg/day #nephjc
Ed @Rx_Ed
@NephJC Vaccination with avacopan likely not required because it's a receptor blocker. Eculizumab is a complement cleavage inhibitor. #NephJC
Joel Topf, MD FACP @kidney_boy
Solid #NephJC w/ 633 Tweets 125 Participants btw 2 Chats. Thanks @KidneyCathy & @DearbhlaKelly4. 📊 https://t.co/NMvBBK8cWS via @symplur
Fra Ian 🇪🇺 @caioqualunque
RT @kidney_boy: Solid #NephJC w/ 633 Tweets 125 Participants btw 2 Chats. Thanks @KidneyCathy & @DearbhlaKelly4. 📊 https://t.co/NMvBBK8cWS…
Nephrology Jrnl Club @NephJC
RT @Rx_Ed: @NephJC Vaccination with avacopan likely not required because it's a receptor blocker. Eculizumab is a complement c…
Dr.Krishna Penmatsa @krishnadoctor1
RT @caioqualunque: @Errantnephron this is from CYCAZAREM now I'll look supplementary files to make a comparison #nephjc. Next tweet in…
Poyan Mehr @poyanmehr
RT @NephJC: Methodology set up for one outcome - but results extrapolated to another. Thx @poyanmehr #nephjc https://t.co/oeSxkJWyJp
Luis Caminal @caminalm
RT @toates_19: Join #NephJC tonight to discuss the CLEAR study in #vasculitis 8pm BST Summary: https://t.co/oeSvlMRvEw https://t.co/eUHfgtL…
soda_troubles @set_fortess
RT @edgarvlermamd: MT @arvindcanchi @ISNeducation ANCA Vasculitis: Factors increasing risk of relapse #Nephpearls #NephJC #WCN2017 🇲🇽 https…
soda_troubles @set_fortess
RT @edgarvlermamd: ANCA Vasculitis: Predictors of treatment relapse/ resistance #Nephpearls #NephJC https://t.co/sBKk4ek8uS
soda_troubles @set_fortess
RT @edgarvlermamd: Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC 👉🏼…
soda_troubles @set_fortess
RT @edgarvlermamd: Birmingham Vasculitis Activity Score (BVAS) #Nephpearls #NephJC https://t.co/bYPpe3xyt2
soda_troubles @set_fortess
RT @edgarvlermamd: Flow diagram for treatment of ANCA Vasculitis ca. 2015 #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/qmnoD…
soda_troubles @set_fortess
RT @edgarvlermamd: Renal Vasculitis #Nephpearls #NephJC https://t.co/M8K8c5qPBo
soda_troubles @set_fortess
RT @edgarvlermamd: Potential therapeutic targets in ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/CCru5MgPfu https://t.co/gdPYNXFu6H
soda_troubles @set_fortess
RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw
Zoran Paunic @unicipa
RT @edgarvlermamd: C-ANCA Chocolate chip cookie 🍪 P-ANCA Popcorn 🍿 Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs
Alex Meraz ⚕🇲🇽 @NephroGuy
RT @NephJC: T1: Interesting study design as exemplified in @kidney_boy visual abstract. Tx for just 12 wks #NephJC https://t.co/rLdiakG1gr
wafaa ar @WafaaArache
RT @kidney_boy: Beta #VisualAbstract for tonight's (and last night's) #NephJC Avacopan for ANCA Associated Vasculitis, a phase 2 tr…
MedReuma @medreuma
RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw
Manish Rathi @manirath
RT @hswapnil: T0: not sure. AAV pretty bad and nasty by itself (esp the renal cases seen by us). Steroids bad, AAV badder? #nephjc
Bárbara Milward @bmilward
RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw
Bárbara Milward @bmilward
RT @edgarvlermamd: C-ANCA Chocolate chip cookie 🍪 P-ANCA Popcorn 🍿 Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs
Dr Mukesh Rulaniya @RulaniyaDr
RT @caioqualunque: @Errantnephron Steroid schedule in CLEAR study looks "standard" #nephjc https://t.co/b9JGEExODs
Dr Mukesh Rulaniya @RulaniyaDr
RT @caioqualunque: @Errantnephron this is from CYCAZAREM now I'll look supplementary files to make a comparison #nephjc. Next tweet in…
#NephJC content from Twitter.